Interluekin-6 inhibitors for the treatment of adult-onset Still's disease.

Abstract

Adult-onset Still's disease is a systemic inflammatory disease characterized by high spiking fever, arthritis, evanescent skin rash, leukocytosis, and hyperferritinemia. The pathogenesis of adult-onset Still's disease has not been fully understood yet; however, multiple proinflammatory cytokines, such as IL-1β and IL-6, play important roles in the development of adult-onset Still's disease. IL-6 is a multifunctional cytokine that accelerates the differentiation of macrophages and cytotoxic T-cells and chemotaxis of neutrophils and macrophages. Serum concentrations of IL-6 well correlate with disease activity of adult-onset Still's disease, and blockade of IL-6 has been proven to be effective in active adult-onset Still's disease. This review will focus on the recent understanding of the role of proinflammatory cytokines of adult-onset Still's disease and the efficacy of IL-6 inhibitors for the treatment of adult-onset Still's disease.

• Authors: Yuko Kaneko
• Journal: Modern rheumatology (Mod Rheumatol) Vol. 32 Issue 1 Pg. 12-15 (Jan 05 2022) ISSN: 1439-7609 [Electronic] England
• PMID: 34894252 (Publication Type: Journal Article, Review)
• Copyright: © Japan College of Rheumatology 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Cytokines
• Interleukin-6

Topics

• Cytokines
• Humans
• Interleukin-6 (antagonists & inhibitors)
• Still's Disease, Adult-Onset (drug therapy)